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Hypoxia, or low oxygen availability, is an important physiological stimulus for multicellular organisms. 
Molecularly, hypoxia induces a transcriptional programme directed at restoration of oxygen homeostasis and 
cellular survival. Hypoxia and inflammation are intricately linked, and even though it is appreciated that NF-κB 
regulates the HIF system, little is known about how HIF regulates NF-κB. In a recent report we have shown that 
HIF-1α has an important role in regulating NF-κB. Importantly, HIF-1α acted to constrain NF-κB 
transcriptional activity, in mammalian cells and in the in vivo genetic model of Drosophila. Reduction of HIF-1α 
resulted in increased levels of specific NF-κB targets, by a mechanism dependent on the TAK/IKK and CDK6 
kinases. Deletion of the HIF-1α homologue in Drosophila, Sima, resulted in heightened sensitivity to infection 
due to uncontrolled NF-κB. This report delineated for the first time the contribution of HIF-1α towards the 
NF-κB pathway, and demonstrated the importance of HIF-1α presence for the restraint of the inflammatory 
response in vivo. The importance of this crosstalk between HIF and NF-κB is significant, as it could create 
potential new therapies in diseases where hypoxia and inflammatory are prevalent.  
To cite this article: Daniel Bandarra, et al. HIF-1α a novel piece in the NF-κB puzzle. Inflamm Cell Signal 2015; 2: e792. 
doi: 10.14800/ics.792. 
 
Oxygen homeostasis is crucially important for the survival 
of all vertebrate species [1]. Therefore, organisms developed a 
way to coordinate the oxygen supply in order to maintain the 
balance that the cells need to function properly. Cells have 
evolved mechanisms to control oxygen levels in the 
intracellular compartments. When these mechanisms fail, and 
the standards of oxygen supply decrease, a stress condition 
called hypoxia is created. Hypoxia is also a relevant 
physiological stress associated with many processes such as 
adaptation to high altitudes and embryo development but also 
involved in many pathological conditions such as cancer, 
heart failure and stroke [2, 3]. An essential component 
responsible to regulate the molecular response to hypoxia in 
the cell is the transcription factor family called Hypoxia 
Inducible Factor (HIF). HIF is a complex of transcription 
factors composed of an α- and a β- subunit. While the α- 
subunit changes with oxygen levels, the β- does not, and it is 
constitutively expressed. The oxygen-dependent control of 
HIF-α is conferred by a class of dioxygenases called 
prolyl-hydroxylases (PHDs), whose catalytic activity marks 
HIF-α for VHL-dependent proteasomal degradation when 
oxygen is present [4]. The hypoxia-responsive HIF complex is 
responsible for the initiation of a transcriptional program to 
hypoxia, and ultimately restoration of oxygen homeostasis [5, 
6]. 
Another important stress of medical relevance is 
Inflammation. Inflammation is a protective attempt to 
eliminate pathogens but is also involved in the initiation of 
the healing process of a wound. Similarly to hypoxia, cells 
have evolved sophisticate mechanisms to control the 
inflammatory response to pathogens [7]. A key element of 
these mechanisms is a family of transcription factors called 
Nuclear Factor κ-light-chain-enhancer of activated B cells 
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(NF-κB). In mammalians, NF-κB is composed of five genes, 
encoding RelA/p65, RelB, cRel, p100/p52 and p105/p50 [8]. 
NF-κB targets are extensive and include genes that control 
many different cellular processes such as proliferation, 
apoptosis, inflammation, migration and cell cycle [8, 9]. This 
family of transcription factors are activated under several 
different stimuli (such as virus, bacteria or cytokines), 
activating several signalling pathways that ultimately engage 
a complex transcriptional program. Importantly, several 
diseases (e.g. cancer and rheumatoid arthritis), result from 
the deregulation of these pathways [10-12].  
Hypoxia and inflammation are intimately connected at the 
cellular, clinical and also at the molecular level [2, 13]. HIF 
(hypoxia) and NF-κB (inflammation) have previously been 
linked at the molecular level [14-16]. On one hand, they share a 
number of common target genes. On the other hand, physical 
and functional interactions between HIF subunits and NF-κB 
have been described [13].  
Our laboratory, and others, have previously demonstrated 
that inflammatory stimuli, such as TNF-α, and bacterial 
products including LPS, led to HIF-1α activation in a NF-κB 
dependent manner in cancer cell lines [14, 17]. These findings 
demonstrated NF-κB as a pivotal regulator of HIF activity 
and expression. However, whether HIF had any role in the 
regulation of the NF-κB pathway had not been elucidated, 
until very recently. Our study, recently published, has 
demonstrated the involvement of HIF in the regulation of 
NF-κB [18]. Using several mammalian cancer cell lines we 
showed that in the absence of HIF-1α, NF-κB activity was 
enhanced. Furthermore, in response to TNF-α several 
NF-κB target genes, such as Cyld, A20, and IκB-α, were 
up-regulated upon HIF-1α siRNA knockdown. These results 
are in line with the idea of HIF having a protective role 
against inflammation. In this case, HIF would work as one of 
the negative feedback loops, so important to restrain NF-κB 
activity, and mediate the response to infection [18]. 
Mechanistically, in our study, we demonstrated that the 
increase in NF-κB activity after HIF depletion required TAK, 
IKK and, at least in part CDK6 kinases [18]. While IKK and 
TAK1 are kinases required for proper TNF-α and hypoxia 
mediated activation of NF-κB [8], CDK6 was previously 
described as a co-activator of NF-κB target genes [19, 20]. Our 
analysis revealed that CDK6 was not only required for the 
HIF-1α mediated-repression of NF-κB, but also for the 
phosphorylation of RelA at the Serine 536 in basal 
conditions (Figure 1). This phosphorylation is particularly 
important, as previous work has described to be important in 
the activation of NF-κB target genes [21]. Furthermore, CDK6 
interaction with RelA at κB promoters had been previously 
shown to be important for NF-κB-dependent expression of 
specific genes [19, 20]. Interestingly, we also showed that in the 
absence of HIF-1α this interaction was enhanced, and 
consequently more RelA-CDK6 was found at the κB 
promoter of the important chemokine IL-8 [18] (Figure 1).  
Our findings were also extended to an in vivo model, using 
Drosophila melanogaster. Drosophila has been instrumental 
to determine the role of NF-κB in infection and inflammation 
[22]. The NF-κB pathway is well conserved and importantly, 
so is the HIF pathway [23]. Deletion of the HIF-α homologue 
in Drosophila, Sima, resulted in hypersensitivity to infection 
due to deregulated NF-κB [18]. Previous work from the 
laboratory had shown that Drosophila HIF-α was activated 
by inflammation in vivo in an IKK-dependent manner [16], 
recapitulating the finding from cell culture work [14, 24]; 
however HIF’s role in such circumstances had not been 
investigated. In our most recent study, we demonstrated that 
Drosophila HIF-α mutant flies had increased levels of the 
NF-κB subunits, and targets genes, which resulted in 
Figure 1: Model of HIF regulation over NF-κB pathway. 
Depletion of HIF-1α led to increase of RelA/CDK6 complex activity, 
increasing the expression of pro-inflammatory cytokines, such as 
IL-8. Additionally, lack of HIF-1α results in increased RelA S536 
phosphorylation, which can also lead to increase of expression of 
inflammatory signals. Whether other HIF subunits, such as HIF-1β, 
or other NF-κB subunits are involved remains unknown. 
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deregulated immune response, and poor survival in response 
to infection [18]. Interestingly, our results suggested that HIF 
was acting mainly through the IMD pathway, which has been 
strongly associated to the inflammatory production of 
antibacterial peptides and mediation of the inflammatory 
response in this model organism [25]. 
So far very few reports have linked HIF with 
inflammation in vivo. In zebrafish, it was shown that HIF 
induction following inflammation resulted in decreased 
neutrophil apoptosis, and consequently in a delayed 
resolution phase of inflammation clearance [26]. On the other 
hand, in mice, HIF has been described as a protective factor 
against inflammation in a colitis model, where mice lacking 
HIF-1α in the intestinal epithelium correlated with more 
severe inflammatory response and mortality [27]. Additional 
reports in mice have also shown HIF protective role in the 
intestine [28, 29]. 
Taking in consideration our findings, and the reports on 
HIF’s role in inflammation, it seems that, depending on cell 
type, HIF-1α can be either pro-inflammatory or 
anti-inflammatory. Even though, it seems clear that HIF 
controls the inflammatory response through the regulation of 
NF-κB, what determines if it acts as an activator or a 
repressor is not. Therefore, it would be interesting to 
investigate the contribution of each HIF and NF-κB subunit 
in the context of inflammation. This analysis should also be 
extended to different cell types such as the immune system 
cell subtypes as well as fibroblasts and additional cancer cell 
models. This would be important not only to understand 
HIF’s antagonistic effects on NF-κB, but also to create 
potential new therapies in inflammatory diseases and cancer.  
In conclusion, our study revealed another piece in the 
puzzle that is NF-κB regulation, in the form of HIF-1α. 
HIF-1α presents itself as a novel negative regulator of 
exacerbated NF-κB activity, for which it modulates the 
activity of TAK-IKK axis as well as CDK6 (Figure 1). 
However, whether HIF-1α requires its binding partner, 
HIF-1β, for this role is currently unclear and future work 
should reveal if this is the case. It does, however, raise the 
interesting possibility of elevating HIF-1α as a potential 
therapeutic in inflammatory diseases. This should be a 
feasible and testable possibility, as several PHD inhibitors, 
known to activate HIF-1α levels and activity, are currently in 
clinical trials for conditions of anaemia [30].  
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